Navigation Links
Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Date:12/11/2012

xpectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
2. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
3. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
5. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
6. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
7. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Double-digit Growth Rate of the Pharmaceuticals Industry in Asia Pacific Boosts the API Market, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Luoxis Diagnostics, Inc., a subsidiary ... announced the presentation of three clinical and preclinical ... broadly applicable and robust research tool capable of ... response to injury, illness, or stress.  In all ... Luoxis, academic and pharmaceutical research partners, RedoxSYS was ...
(Date:11/24/2014)... 24, 2014 The Female Health Company (NASDAQ-CM: ... conference call to discuss its operating results for the ... on Tuesday, December 2, 2014 at 11:00 a.m. Eastern ... operating results earlier the same day. Shareholders ... call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and ...
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
Breaking Medicine Technology:Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... Pre-Clinical Results Demonstrate Potential of ONCONASE for,Treatment ... /PRNewswire-FirstCall/ --,Alfacell Corporation today announced that new ... is active against naive and,chemoresistant neuroblastoma cells. ... vivo data published in Cancer,Letters (2007; Vol. ...
... WIRE)--Jun 27, 2007 - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), ... of cell therapies, presented,poster presentations at the ... Meeting (ISSCR) in Cairns, Queensland, Australia,from June ... of the International,Society for Cellular Therapy (ISCT) ...
Cached Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
(Date:11/23/2014)... holidays can be a challenge for families of children ... an expert says. "Holidays with family can be ... have children with special needs, some care must be ... of the Sciences in Philadelphia, said in a university ... or visitors know what special requirements are needed to ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 This ... such as its significance, programs and manufacturing technological ... Chinese suppliers major market gamers in information. In ... item specifications, prospective, manufacturing value, and 2009-2014 market ... the evaluation symbolizes the globally and Chinese suppliers ...
(Date:11/23/2014)... 2014 SWAccessControl.com's high quality access control ... the company has announced its new collection of power ... these high quality power suppliers. All the new models ... special offer lasts until Dec. 20, 2014. , SWAccessControl.com ... have been supporting it for a long time. It ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, offering ... “If you are looking for gorgeous beach wedding dresses ... Here you can enjoy 70% off discounts and all ... big marriage ceremony is the most important dream of ... is uppermost priority. Ophelia, one of customers, said, “I ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... 17, 2008 A new study in the Review ... meals at restaurants. Results show that both are larger and ... typical fast food meal being smaller and having fewer calories ... , James K. Binkley of Purdue University used data from ...
... , WASHINGTON, Dec. 17 ... A Call for Action: Enabling Healthcare Reform Using Information ... for the Obama Administration and 111th Congress to harness IT,s ... , "President-elect Obama and U.S. ...
... (SDSU) and the Moores Cancer Center at the University ... forces to help explain and eliminate cancer disparities. The ... Institute (NCI) of the National Institutes of Health will ... San Diego region with the goal of reducing differences ...
... 2008 - Elsevier, world-leading publisher of scientific, technical, and ... that, beginning in January 2009, the internationally respected ... ) (http://www.jpsmjournal.com) will be the official journal of the ... The JPSM will continue to serve as ...
... Therapeutics (Prime), a,nationwide pharmacy benefit management (PBM) company, ... as Chief Marketing Officer,(CMO). , ... , As ... marketing,strategy, product development and other market-related initiatives. He ...
... Frank, a medical doctor and,researcher at the University of ... remedy sickness and save lives should have access to the,best ... located near,research institutions in wealthy countries. , ... Frank,s idea led her to ...
Cached Medicine News:Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 2Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 3Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 4Health News:$15 million grant awarded to reduce cancer disparities 2Health News:$15 million grant awarded to reduce cancer disparities 3Health News:$15 million grant awarded to reduce cancer disparities 4Health News:Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM 2Health News:Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer 2Health News:Vivisimo Search Delivers Medical Knowledge to Global Health-Care Community 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: